NCT00886574

Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events

Multi-Center, Randomized, Open Label Study of the Efficacy of Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events With Korean Type 2 DM Patients

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Hanyang University · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This multi-center, randomized controlled study aims to evaluate the efficacy of Cilostazol versus Aspirin for primary prevention of atherosclerotic events with Korean type 2 Diabetes Mellitus (DM) patients.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Cilostazol	Cilostazol 200 mg (50 mg 2T twice per day)
DRUG	Aspirin	100 mg once a day

Timeline

• Start date: 2009-04-01
• Primary completion: 2011-02-01
• Completion: 2014-02-01
• First posted: 2009-04-23
• Last updated: 2010-06-04

Locations

6 sites across 1 country: South Korea